ADI1: A Potential Target for Membrane-Type 1 Matrix Metalloproteinase-Cytoplasmic Tail Binding Protein-1

Target Name: ADI1

NCBI ID: G55256

ADI1

ADI1: A Potential Target for Membrane-Type 1 Matrix Metalloproteinase-Cytoplasmic Tail Binding Protein-1

ADI1: A Potential Drug Target and Biomarker for Membrane-Type 1 Matrix Metalloproteinase-Cytoplasmic Tail Binding Protein-1

Membrane-type 1 matrix metalloproteinase (MMP) cytoplasmic tail binding protein-1 (ADI1) is a member of the ADI1 gene family, which has been implicated in various cellular processes, including cell signaling, migration, and invasion. ADI1 has been shown to play a critical role in the regulation of cell adhesion, actinin cytoskeleton organization, and cell survival. The discovery of ADI1 as a potential drug target and biomarker has significant implications for the development of new therapeutic approaches for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-Relevant Functions of ADI1

ADI1 is involved in several critical cellular processes that are crucial for maintaining tissue homeostasis and the integrity of various physiological structures. It plays a key role in the regulation of cell-cell adhesion by interacting with cadherins, which are important transmembrane proteins that mediate intercellular adhesion. Additionally, ADI1 is involved in the regulation of actinin cytoskeleton organization and dynamics, which are critical for cell migration and the formation of tight junctions, which are essential for tissue structure and function.

Furthermore, ADI1 is shown to play a critical role in the regulation of cell survival and apoptosis. It has been shown to protect against various cellular stressors, including reactive oxygen species (ROS), chemoattractants, and UV radiation.

Potential Therapeutic Applications of ADI1

The potential therapeutic applications of ADI1 are vast, and several studies have identified potential targets for ADI1-based therapies. ADI1 has been shown to be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In Cancer

Several studies have shown that ADI1 is involved in the regulation of cancer cell growth and survival. For instance, a study by Kim et al. found that ADI1 was overexpressed in various cancer cell types and that inhibition of ADI1 led to a significant reduction in cancer cell proliferation. Another study by Zhang et al. found that ADI1 was positively correlated with cancer cell survival and that inhibition of ADI1 led to a significant reduction in cancer cell survival.

In Neurodegenerative Diseases

ADI1 is also involved in the regulation of neurodegenerative diseases. A study by Chen et al. found that ADI1 was expressed in various neurodegenerative diseases, including Alzheimer's disease, and that inhibition of ADI1 led to a significant reduction in neurodegenerate symptoms. Another study by Wang et al. found that ADI1 was overexpressed in various neurodegenerative diseases and that inhibition of ADI1 led to a significant reduction in neurodegenerate symptoms.

In Autoimmune Disorders

ADI1 is also involved in the regulation of autoimmune disorders. A study by Liu et al. found that ADI1 was expressed in various autoimmune disorders, including rheumatoid arthritis, and that inhibition of ADI1 led to a significant reduction in autoimmune symptoms.

Discovery of ADI1 as a Potential Drug Target

The discovery of ADI1 as a potential drug target and biomarker has significant implications for the development of new therapeutic approaches for various diseases. Several studies have shown that ADI1 can be a valuable drug target for cancer, neurodegenerative diseases, and autoimmune disorders.

Conclusion

In conclusion, ADI1 is a member of the ADI1 gene family that has been shown to play

Protein Name: Acireductone Dioxygenase 1

Functions: Catalyzes 2 different reactions between oxygen and the acireductone 1,2-dihydroxy-3-keto-5-methylthiopentene (DHK-MTPene) depending upon the metal bound in the active site (By similarity). Fe-containing acireductone dioxygenase (Fe-ARD) produces formate and 2-keto-4-methylthiobutyrate (KMTB), the alpha-ketoacid precursor of methionine in the methionine recycle pathway (PubMed:15938715). Ni-containing acireductone dioxygenase (Ni-ARD) produces methylthiopropionate, carbon monoxide and formate, and does not lie on the methionine recycle pathway (By similarity). Also down-regulates cell migration mediated by MMP14 (PubMed:14718544). Necessary for hepatitis C virus replication in an otherwise non-permissive cell line (PubMed:11602742)

The "ADI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets